2019 Annual Meeting | C76 - Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions

Date Sunday 05/05/19

Time 03:30 PM - 05:30 PM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Michael D. Geschwind, MD, PhD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should be familiar with the differential diagnosis of prion and antibody-mediated causes of RPD and the clinical presentation and evaluation of the more common conditions.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Program Tracks Advanced Practice Provider

Recommended Audience General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider

Teaching Styles Case-based, Interactive, Audience Participation

Program Materials Program Evaluations

Event Timeline
03:30 PM - 03:35 PM EDT	Speaker	Introduction Michael D. Geschwind, MD, PhD, FAAN
03:35 PM - 04:25 PM EDT	Speaker	Infections as Rapidly Progressive Dementia Allen J. Aksamit, Jr., MD, FAAN
04:25 PM - 05:15 PM EDT	Speaker	Autoimmune Causes of Rapidly Progressive Dementia Jeffrey M. Gelfand, MD, MAS, FAAN
05:15 PM - 05:30 PM EDT	Speaker	Questions and Answers
05:30 PM - 06:00 PM EDT	Discussion	Continuing the Conversation

Faculty Disclosures
Michael D. Geschwind, MD, PhD, FAAN	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Allen J. Aksamit, Jr., MD, FAAN	Dr. Aksamit has nothing to disclose.
Jeffrey M. Gelfand, MD, MAS, FAAN	Dr. Gelfand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.